Cancer Research

Blood test may help doctors catch pancreatic cancer early

A blood test may be able to detect the most common form of pancreatic cancer while it is still in its early stages while also helping doctors accurately stage a patient’s disease and guide them to the appropriate treatment.

John Infanti

Media Contact


In the News

New Scientist

CRISPR cancer trial finds that gene-edited immune cells are safe

Edward Stadtmauer and Carl June of the Perelman School of Medicine spoke about a clinical trial that found it safe to inject CRISPR gene-edited immune cells into people with advanced cancer.



Deciphering a cancer treatment’s dark side

Saar Gill of the Perelman School of Medicine said it would be easier to treat cancer using CAR-T cell therapy without the looming possibility of triggering cytokine release syndrome.


Scientific American

Could immunotherapy treat diseases besides cancer?

Jonathan Epstein of the Perelman School of Medicine is quoted on how immunotherapy has transformed cancer care.


Philadelphia Inquirer

The world’s first T-cell therapy for a solid tumor cancer is made in Philly

Carl June of the Perelman School of Medicine commented on news of Iovance Biotherapeutics’ new facilities in South Philadelphia. “Recent advances in the understanding of cancer and the immune system have made a compelling case that [tumor-infiltrating lymphocyte] therapy could be effective in diverse cancers beyond melanoma, such as lung cancer and cervical cancer,” he said. “The decision of Iovance to conduct commercial scale manufacturing in the Philadelphia Navy Yard is wonderful news.”


U.S. News & World Report

Fertility after cancer

Christos Coutifaris and Clarisa Gracia of the Perelman School of Medicine spoke about patients’ fertility options after cancer treatment.


ABC News

Experts offer new recommendations for screening more women for breast cancer

Susan Domcheck of the Basser Center for BRCA at the Abramson Cancer Center said that while new recommendations for the screening for BRCA1 and 2 gene mutations are “very valuable,” they don’t address many persistent problems. She stressed the need for additional research regarding BRCA mutations and risk factors, including the effect of race, ethnicity and socioeconomic status.